> top > docs > PMC:7696151 > spans > 75557-75833 > annotations

PMC:7696151 / 75557-75833 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2179 108-111 Chemical denotes HCQ MESH:D006886
2180 135-145 Chemical denotes trametinib MESH:C560077
2198 191-216 Disease denotes reduction of tumor lesion MESH:D051437
2199 235-240 Disease denotes tumor MESH:D009369
2200 253-259 Disease denotes cancer MESH:D009369
2201 271-275 Disease denotes pain MESH:D010146

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T145 204-209 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T146 235-240 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T147 253-259 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T148 271-275 Phenotype denotes pain http://purl.obolibrary.org/obo/HP_0012531

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T485 0-276 Sentence denotes For this reason, Drucker and Rosen [144] performed an off-label trial with an association of 400–1200 mg of HCQ and a constant dose of trametinib, observing a partial response with a general reduction of tumor lesion size, circulating tumor markers and cancer-associated pain.